ICON Cancer Centre Wesley

The trials here

What the 16 trials at this site are about, from their registry records.

Conditions

• Lung cancer3 trials
• Ovarian cancer3 trials
• Prostate cancer3 trials
• Bladder cancer2 trials
• Diffuse large B-cell lymphoma2 trials
• Follicular lymphoma2 trials
• Kidney cancer2 trials
• Cervical cancer1 trial
• Chronic lymphocytic leukaemia1 trial
• Colorectal cancer1 trial
• Endometrial cancer1 trial
• Gastric and oesophageal cancer1 trial
• and 7 more

Phase

• Phase 311 trials
• Phase 1/22 trials
• Phase 22 trials
• Phase 11 trial

Status

• Recruiting9 trials
• Active, not recruiting5 trials
• Completed2 trials

Lead sponsor

• Pfizer4 trials
• Regeneron Pharmaceuticals3 trials
• BeiGene2 trials
• Eli Lilly and Company2 trials
• Allogene Therapeutics1 trial
• and 4 more

Running trials

• Recruiting

  Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer

  NCT07421700· Phase 1/2· Pfizer· Source

• Recruiting

  Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer

  NCT07227415· Phase 1/2· Pfizer· Source

• Recruiting

  Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

  NCT06890598· Phase 3· Eli Lilly and Company· Source

  Contact: Adam Stirling (principal investigator)

• Recruiting

  Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)

  NCT06819007· Phase 3· Daiichi Sankyo· Source

• Active, not recruiting

  A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).

  NCT06551324· Phase 3· Pfizer· Source

• Recruiting

  Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

  NCT06500273· Phase 2· Allogene Therapeutics· Source

  Contact: Karthik Nath, MD (principal investigator)

• Recruiting

  A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

  NCT06072781· Phase 3· Verastem, Inc.· Source

  Contact: Amy Morrow

• Recruiting

  A Study of MGC026 in Participants With Advanced Solid Tumors

  NCT06242470· Phase 1· MacroGenics· Source

  Contact: Global Trial Manager

• Recruiting

  A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

  NCT06119581· Phase 3· Eli Lilly and Company· Source

  Contact: Adam Stirling (principal investigator)

• Recruiting

  A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma

  NCT06091865· Phase 3· Regeneron Pharmaceuticals· Source

  Contact: Clinical Trials Administrator

• Recruiting

  A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma

  NCT05730036· Phase 3· Regeneron Pharmaceuticals· Source

  Contact: Clinical Trials Administrator

• Active, not recruiting

  Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy

  NCT05840211· Phase 3· Gilead Sciences· Source

• Active, not recruiting

  Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC

  NCT03395197· Phase 3· Pfizer· Source

• Active, not recruiting

  A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL

  NCT03336333· Phase 3· BeiGene· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer3 recruiting
• Ovarian cancer3 recruiting
• Bladder cancer2 recruiting
• Diffuse large B-cell lymphoma2 recruiting
• Kidney cancer2 recruiting
• Cervical cancer1 recruiting
• Colorectal cancer1 recruiting
• Endometrial cancer1 recruiting
• Gastric and oesophageal cancer1 recruiting
• Head and neck cancer1 recruiting
• Liver and biliary tract cancer1 recruiting
• Melanoma1 recruiting
• Pancreatic cancer1 recruiting
• Prostate cancer1 recruiting
• Sarcoma1 recruiting

Closed trials

• Recruiting

  A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma

  NCT06091254· Phase 3· Regeneron Pharmaceuticals· Source

  Contact: Clinical Trials Administrator

• Completed

  A Study Comparing Obinutuzumab and BGB-3111 Versus Obinutuzumab Alone in Treating R/R Follicular Lymphoma

  NCT03332017· Phase 2· BeiGene· Source